Authored by: Darrin Beaupre, M.D., Ph.D., Chief Medical Officer
At IDEAYA, progress starts with a single idea—one rooted in deep biological insight and a belief that we can do better for patients. IDEAYA Ideas is a platform to explore how those ideas take shape, evolve through science and collaboration, and ultimately translate into meaningful innovation. It's a window into the thinking behind our work—and how bold ideas can help redefine what’s possible for those with hard-to-treat cancers.
Many organizations talk about transforming lives though it is not always clear how that commitment is brought to life in meaningful ways. For us, it starts with identifying where biology offers real opportunity to intervene—and committing to follow that science all the way to the patients. Uveal melanoma (UM) is one of those places.
From the outset, we recognized it as a long-overlooked cancer with clear unmet need and a biology that pointed toward new possibilities. It’s often grouped with cutaneous melanoma, but from a biological standpoint, it’s a very different disease. In most patients, UM is driven by mutations in GNAQ or GNA11 that lead to persistent activation of PKC signaling. That pathway remains active throughout the course of disease, including in the metastatic setting.
From a drug development perspective, that kind of consistent dependency is exactly what you look for. It suggests there’s a central mechanism you can target. But historically, that hasn’t translated into effective therapies for patients. That disconnect is part of what makes uveal melanoma so challenging.
Why uveal melanoma remains difficult to treat
About half of patients will eventually develop metastatic disease, and once they do, outcomes remain poor. The disease doesn’t respond the same way as other cancers that typically respond to immunotherapy. It has a low mutational burden, which limits immune recognition, and when it spreads, it typically involves the liver, where the tumor microenvironment further supports tumor survival. As a result, therapies that are work in diseases such as cutaneous melanoma haven’t had the same impact here.
Treatment options today are limited. Some are restricted to specific patient subgroups, and others provide modest and often short-lived benefit. More importantly, none of these approaches were designed to directly address the core biology that’s driving the disease. That’s where we think a precision medicine approach can make a difference.
A precision medicine approach to a defined target
Uveal melanoma was one of the first places we chose to focus, and is the most advanced product in our pipeline, for good reason: it sits at the intersection of high unmet need and clearly defined tumor biology. If you can target the right dependency, there’s a real opportunity to change outcomes.
Recent clinical data from our ongoing OptimUM-02 trial suggest that targeting key pathways translates into meaningful clinical activity, as we have observed when evaluating darovasertib in combination with crizotinib in first-line HLA-A*02:01-negative metastatic uveal melanoma. This is a patient population that has historically had no approved systemic treatment options.
The rationale behind that combination is straightforward. You target PKC signaling as a central driver, and you combine it with additional pathway inhibition to address mechanisms of resistance and tumor survival. That’s the kind of strategy we think is required in this disease.
Translating biology into meaningful outcomes
For patients, the impact of this disease is significant. Primary treatment can affect vision, and even when local disease is controlled, there’s an ongoing risk of progression. When metastasis occurs, the lack of effective options becomes very real.
What's clear to me is that the biology of uveal melanoma has been pointing us in the right direction for some time. The challenge has been translating that into therapies that actually make a difference for patients.
At IDEAYA, that’s what we’re working to do: identify the key tumor dependencies, design therapies to target them, and move as quickly as we can to bring those therapies to patients with the greatest unmet need. We see this as our responsibility. If we can do that successfully, there’s an opportunity not just to improve outcomes, but to fundamentally change how diseases are treated.
For healthcare professionals looking to explore the biology, clinical challenges, and emerging approaches in uveal melanoma in greater depth, visit https://www.viewuvealmelanomadifferently.com.
